Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.